{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:28:27Z","timestamp":1787506107387,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":1356,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009298","name":"Raptor Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1111\/ajt.15081","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T06:39:27Z","timestamp":1534747167000},"page":"811-822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial"],"prefix":"10.1016","volume":"19","author":[{"given":"Burkhard","family":"T\u00f6nshoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ettenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Dello Strologo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Helio","family":"Tedesco-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Djouher","family":"Martzloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.15081_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trre.2013.04.003","article-title":"The impact of calcineurin inhibitors on graft survival","volume":"27","author":"Rush","year":"2013","journal-title":"Transplant Rev."},{"key":"10.1111\/ajt.15081_bib2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1517\/14740338.2015.1083974","article-title":"The safety of calcineurin inhibitors for kidney-transplant patients","volume":"14","author":"Malvezzi","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"10.1111\/ajt.15081_bib3","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s11255-014-0783-1","article-title":"Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis","volume":"46","author":"Su","year":"2014","journal-title":"Int Urol Nephrol."},{"key":"10.1111\/ajt.15081_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet."},{"key":"10.1111\/ajt.15081_bib5","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation","volume":"12","author":"Mj\u00f6rnstedt","year":"2012","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15081_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation."},{"key":"10.1111\/ajt.15081_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation."},{"key":"10.1111\/ajt.15081_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CN108444","article-title":"Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study","volume":"83","author":"Budde","year":"2015","journal-title":"Clin Nephrol."},{"key":"10.1111\/ajt.15081_bib9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15081_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfm621","article-title":"A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine","volume":"23","author":"Montagnino","year":"2008","journal-title":"Nephrol Dial Transplant."},{"key":"10.1111\/ajt.15081_bib11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transplant Int."},{"key":"10.1111\/ajt.15081_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.trre.2015.09.001","article-title":"Everolimus immunosuppression in kidney transplantation: what is the optimal strategy?","volume":"30","author":"Witzke","year":"2016","journal-title":"Transplant Rev."},{"key":"10.1111\/ajt.15081_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1432-2277.2010.01140.x","article-title":"Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?","volume":"24","author":"Zeier","year":"2011","journal-title":"Transpl Int."},{"key":"10.1111\/ajt.15081_bib14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"10.1111\/ajt.15081_bib15","doi-asserted-by":"crossref","first-page":"e0135439","DOI":"10.1371\/journal.pone.0135439","article-title":"Efficacy and safety of an everolimus- vs a mycophenolate mofetil-based regimen in pediatric renal transplant recipients","volume":"10","author":"Brunkhorst","year":"2015","journal-title":"PloS One."},{"key":"10.1111\/ajt.15081_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/ajt.13649","article-title":"Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation","volume":"16","author":"H\u00f6cker","year":"2016","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15081_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/petr.12035","article-title":"De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study","volume":"17","author":"Grushkin","year":"2013","journal-title":"Pediatr Transplant."},{"key":"10.1111\/ajt.15081_bib18","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1600-6143.2010.03266.x","article-title":"De novo therapy with everolimus, low-dose cyclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation","volume":"10","author":"Pape","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15081_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1399-3046.2007.00832.x","article-title":"Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year","volume":"12","author":"Ettenger","year":"2008","journal-title":"Pediatr Transplant."},{"key":"10.1111\/ajt.15081_bib20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/TP.0b013e3182295bed","article-title":"Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data","volume":"92","author":"Pape","year":"2011","journal-title":"Transplantation."},{"key":"10.1111\/ajt.15081_bib21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/petr.12261","article-title":"Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients","volume":"18","author":"Ferraresso","year":"2014","journal-title":"Pediatr Transplant."},{"key":"10.1111\/ajt.15081_bib22","doi-asserted-by":"crossref","first-page":"e0146523","DOI":"10.1371\/journal.pone.0146523","article-title":"Steroid avoidance or withdrawal regimens in paediatric kidney transplantation: a meta-analysis of randomised controlled trials","volume":"11","author":"Zhang","year":"2016","journal-title":"PloS One."},{"key":"10.1111\/ajt.15081_bib23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/TP.0000000000001320","article-title":"Corticosteroid use and growth after pediatric solid organ transplantation: a systematic review and meta-analysis","volume":"101","author":"Tsampalieros","year":"2017","journal-title":"Transplantation."},{"key":"10.1111\/ajt.15081_bib24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"10.1111\/ajt.15081_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/0091270002239822","article-title":"Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics","volume":"43","author":"Kovarik","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"10.1111\/ajt.15081_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-6143.2009.02987.x","article-title":"Banff \u201809 meeting report: antibody mediated graft deterioration and implementation of Banff working groups","volume":"10","author":"Sis","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15081_bib27","unstructured":"Centers for Disease Control and Prevention. 2000. https:\/\/www.cdc.gov\/growthcharts\/index.htm 2000 CDC Growth Charts for the United States: Methods and Development. Accessed September 20, 2018."},{"key":"10.1111\/ajt.15081_bib28","unstructured":"Centers for Disease Control and Prevention Percentile Data Files with LMS values. https:\/\/www.cdc.gov\/growthcharts\/percentile_data_files.htm. Accessed September 20, 2018."},{"key":"10.1111\/ajt.15081_bib29","unstructured":"North American Paediatric Renal Transplant Cooperative Study (NAPRTCS). Annual Report; 2008. https:\/\/web.emmes.com\/study\/ped\/annlrept\/Annual%20Report%20-2008.pdf. Accessed September 20, 2018."},{"key":"10.1111\/ajt.15081_bib30","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15081_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1399-3046.2006.00651.x","article-title":"Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A","volume":"11","author":"Pape","year":"2007","journal-title":"Pediatr Transplant."},{"key":"10.1111\/ajt.15081_bib32","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/ajt.14169","article-title":"Relationship among viremia\/viral infection, alloimmunity, and nutritional parameters in the first year after pediatric kidney transplantation","volume":"17","author":"Ettenger","year":"2017","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15081_bib33","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15081_bib34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2215\/CJN.02180314","article-title":"Patterns of growth after kidney transplantation among children with ESRD","volume":"10","author":"Franke","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1111\/ajt.15081_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/petr.12186","article-title":"Long-term experience of steroid-free pediatric renal transplantation: effects on graft function, body mass index, and longitudinal growth","volume":"18","author":"Wittenhagen","year":"2014","journal-title":"Pediatr Transplant."},{"key":"10.1111\/ajt.15081_bib36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/tri.12148","article-title":"Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients","volume":"26","author":"Billing","year":"2013","journal-title":"Transpl Int."},{"key":"10.1111\/ajt.15081_bib37","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1097\/TP.0000000000001037","article-title":"Pubertal development in pediatric kidney transplant patients receiving mammalian target of rapamycin inhibitors or conventional immunosuppression","volume":"100","author":"F\u00f6rster","year":"2016","journal-title":"Transplantation."},{"key":"10.1111\/ajt.15081_bib38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00467-013-2459-y","article-title":"Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation","volume":"28","author":"Kranz","year":"2013","journal-title":"Pediatr Nephrol."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15081","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522089936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522089936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:24:27Z","timestamp":1761629067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522089936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1600613522089936"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15081","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}